Key Takeaways
- Shares of Boston Scientific plummeted approximately 10% following management’s announcement of reduced full-year organic growth projections to 6.5%–8% during Bernstein’s Strategic Decisions Conference.
- Management projected Q2 organic growth of merely 5%–7%, significantly below market expectations.
- For the first time, WATCHMAN procedure volumes experienced a decline beginning in February, accompanied by softness in EP and Urology divisions.
- The stock reached a fresh 52-week low at $50.75 during intraday trading, reflecting a nearly 46% decline over the past twelve months.
- The majority of Wall Street research firms maintain Buy or Overweight recommendations, with target prices spanning from $60 to $90.
Shares of Boston Scientific Corp (BSX) tumbled approximately 10% during morning trading hours on May 27 following remarks from CEO Mike Mahoney and Chief Medical Officer Dr. Janar Sathananthan at Bernstein’s 42nd Annual Strategic Decisions Conference, where they announced downward revisions to guidance.
Boston Scientific Corporation, BSX
The shares touched an intraday bottom of $50.75, marking a new 52-week low, before staging a modest rebound. As of the latest trading data, BSX was changing hands near $52.79, representing a decline of approximately 10% for the session.
The conference presentation, consisting of a 50-minute question-and-answer segment commencing at roughly 8:00 a.m. Eastern Time, was not anticipated to be the venue for a guidance adjustment. Nevertheless, that’s precisely what transpired.
Executives reduced the full-year organic growth projection to 6.5%–8%, while establishing Q2 organic growth expectations at a mere 5%–7%. Both figures failed to reassure the investment community.
The medical device manufacturer attributed the weakness to three principal areas: electrophysiology (EP), WATCHMAN, and Urology divisions. Notably, WATCHMAN procedure volumes experienced their inaugural decline commencing in February — a development that particularly concerned investors who had been monitoring that business segment.
Executives noted robust demand in concomitant WATCHMAN procedures while highlighting a substantial deceleration in standalone cases. Hospital capacity limitations and reimbursement modifications are being cited as contributing factors.
Wall Street’s Response
The guidance revision intensified what was already a challenging period for analyst opinions surrounding BSX.
Daiwa had previously downgraded the shares to Neutral from Outperform, slashing its price objective to $60 from $83. BofA reduced its target to $68 from $105, while maintaining a Buy recommendation.
However, not all research firms are adopting a bearish stance. Truist Securities maintained a Buy rating with an $85 price objective following a separate $1.5 billion equity commitment in MiRus. TD Cowen preserved its Buy rating with an $80 target. Piper Sandler retained its Overweight rating and $90 objective.
The substantial spread in price targets — ranging from $60 to $90 — underscores the significant uncertainty surrounding the stock at present.
Factors Pressuring Shares
Beyond the guidance reduction itself, executives highlighted tariff-related margin compression as an additional challenge. Competitive market share losses in EP represent another area of concern.
BSX had already experienced selling pressure during the preceding 30 days as growth anxieties intensified regarding the EP and WATCHMAN divisions. Today’s conference commentary simply quantified what market participants had been anticipating.
The broader equity markets offered little support. The S&P 500 and Nasdaq traded essentially unchanged on the session, while the Dow Jones posted only modest gains. BSX faced its challenges independently.
During last month’s earnings conference call, CEO Mahoney characterized the circumstances as “unanticipated headwinds and changing business patterns.” He employed identical language during the Bernstein presentation.
InvestingPro analysis currently indicates BSX appears undervalued compared to its Fair Value assessment. The stock’s PEG ratio stands at 0.32, which generally suggests potential value for growth-focused market participants.
The corporation also maintains a $5 billion share repurchase authorization, with $3 billion remaining available — and recently executed a $2 billion accelerated share repurchase transaction.
BSX’s FRACTURE pivotal study for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter achieved its primary safety and effectiveness objectives, recruiting 420 participants throughout the United States and Europe.
